中药联合阿托伐他汀对冠状动脉临界病变冠心病患者预后及血脂、炎症反应的影响

Influence of Traditional Chinese Medicine Combined with Atorvastatin on Prognosis,Blood Lipid and Inflammation in Borderline Lesion Coronary Heart Disease

目的:探讨中药联合阿托伐他汀对冠状动脉临界病变冠心病患者预后及血脂、炎症反应的影响。方法:将毕节市传染病院诊治经64层螺旋CT证实的156例冠状动脉临界病变患者随机分入对照组与观察组,两组患者均接受冠心病西医常规治疗及阿托伐他汀口服,观察组患者同时接受益气温阳活血方中药治疗。比较两组患者临床疗效、心血管事件发生率、血脂及血清炎症因子的改变。结果:观察组治疗有效率为92.5%,显著高于对照组76.3%(P<0.05);观察组与对照组心血管事件发生率分别为16.3%和38.2%,差别具有统计学意义(P<0.05);观察组治疗后胆固醇(TC)、低密度脂蛋白(LDL-C)及甘油三酯(TG)显著低于对照组(P<0.05);两组治疗后血清炎症因子超敏-C反应蛋白(hs-CRP)、白细胞介素-6(IL-6)及肿瘤坏死因子-α(TNF-α)均显著下降,但观察组上述指标显著优于对照组(P<0.05)。结论:中药联合阿托伐他汀可显著降低冠状动脉临界病变冠心病患者血脂及血清炎症因子水平,减少心血管事件发生率。

Objective： To explore the effect of traditional Chinese medicine combined with atorvastatin on prognosis, blood lipid and inflammation in borderline lesion coronary heart disease. Method： One hundred and fifty-six cases with borderline lesion coronary heart disease diagnosed by 64-row multi-detector computed tomography were randomly divided into control group and observation group. Two groups received both routine treatment and atorvastatin therapy, meanwhile, observation group was given warming yang promoting blood circulation treatment. Clinical effect, major cardiovascular event, blood lipid and serum inflammatory factors were compared between two groups. Result： The effective rate of treatment in observation group was 92.5%, which was much higher than that in control group （76.3%, P 〈0.05）; major cardiovascular events were 16.3% and 38.2% in observation group and control group respectively with significant difference （P 〈 0.05）. After 6 months of treatment, total cholesterol （ TC ）, triglyceride （TG） and low density lipoprotein （ LDL-C ） in observation group were much lower than those in control group （ P 〈 0. 05 ） ; serum high-sensitivity C-creactive protein （ hs- CRP）, interleukin-6 （IL-6） and tumor necrosis factor-α （TNF-α） after treatment greatly decreased in control group and experience group, which in observation group were superior to control group （P 〈 0.05）. Conclusion： Traditional Chinese medicine combined with atorvastatin for borderline lesion coronary heart disease significantlydecrease the blood lipid, serum inflammatory factors and major cardiovascular events.